Finanzas de Aura Biosciences, Inc. (AURA)AURAAura Biosciences, Inc.

Evaluating the bottom line, Aura Biosciences, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -53.49%, provide a clear picture of how effectively AURA converts its operational activities into shareholder value.

In the context of the broader market, AURA competes directly with industry leaders such as PRME and ATTO. With a market capitalization of $669.93M, it holds a significant position in the sector. When comparing efficiency, AURA's gross margin of N/A stands against PRME's 100.00% and ATTO's 100.00%. Such benchmarking helps identify whether Aura Biosciences, Inc. is trading at a premium or discount relative to its financial performance.

Aura Biosciences has reported consistent net losses, with Q2 2026 showing a loss of $45.64 million, up from $26.13 million in Q2 2025. The current ratio is strong at 16.82, indicating good short-term financial health, but the overall trend is negative with a forward P/E of 0 and a price-to-sales ratio of 0.